Product Information
Registration Status: ActiveSIN15291P
AZILECT TABLET 1MG is approved to be sold in Singapore with effective from 2017-07-07. It is marketed by LUNDBECK SINGAPORE PTE LTD, with the registration number of SIN15291P.
This product contains Rasagiline 1mg in the form of CAPSULE, LIQUID FILLED. It is approved for ORAL use.
This product is manufactured by Teva Pharmaceutical Industries in ISRAEL.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Indication
For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Mechanism of Action
The precise mechanisms of action of rasagiline is unknown. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline's beneficial effects seen in models of dopaminergic motor dysfunction.
Pharmacokinetics
- Absorption
- Rasagiline is rapidly absorbed following oral administration. The absolute bioavailability of rasagiline is about 36%.
- Distribution
- * 87 L
- Metabolism
- Rasagiline undergoes almost complete biotransformation in the liver prior to excretion. In vitro experiments indicate that both routes of rasagiline metabolism are dependent on the cytochrome P450 (CYP) system, with CYP 1A2 being the major isoenzyme involved in rasagiline metabolism.
- Elimination
Toxicity
Signs and symptoms of overdosage may include, alone or in combination, any of the following: drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions, and coma; rapid and irregular pulse, hypertension, hypotension and vascular collapse; precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin.
Active Ingredient/Synonyms
(1R)-N-Propargylindan-1-amine | (R)-Indan-1-yl-prop-2-ynyl-amine | (R)-N-2-Propynyl-1-indanamine | RAS | Rasagiline |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.